Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ML228 is a potent the Hypoxia Inducible Factor (HIF) pathway activator with EC50 of 1 μM. ML228 potently activates HIF in vitro as well as its downstream target VEGF.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 37.00 | |
5 mg | In stock | $ 89.00 | |
10 mg | In stock | $ 163.00 | |
25 mg | In stock | $ 359.00 | |
50 mg | In stock | $ 562.00 | |
100 mg | In stock | $ 790.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 98.00 |
Description | ML228 is a potent the Hypoxia Inducible Factor (HIF) pathway activator with EC50 of 1 μM. ML228 potently activates HIF in vitro as well as its downstream target VEGF. |
In vitro | ML228 introduces a new chemical class for researchers exploring HIF activation and its therapeutic applications. Unlike existing HIF activators, ML228's structure significantly diverges, notably absent of the acidic functional group typically found in PHD inhibitors—an attribute potentially crucial for specific disease contexts[1][2]. |
In vivo | ML228 (injection; 1 µg/kg; 7 days) treatments following spinal cord injury (SCI) improves the local hypoxic ischemia environment, reduces SCI secondary injury and promotes the recovery of neurological function[3]. |
Molecular Weight | 415.49 |
Formula | C27H21N5 |
CAS No. | 1357171-62-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 30 mg/mL (72.2 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ML228 1357171-62-0 Angiogenesis Chromatin/Epigenetic HIF ML 228 ML-228 inhibitor inhibit